 PLANEGGMUNICH, GERMANY ACCESSWIRE January 6, 2021 MorphoSys AG FSE:MOR; Prime Standard Segment; MDAX TecDAX; NASDAQ:MOR, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will lead all corporate finance functions as a member of the Management Board of MorphoSys AG. 